Patheon NV Company Profile (NASDAQ:PTHN)

About Patheon NV

Patheon NV logoPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTHN
  • CUSIP:
Key Metrics:
  • Previous Close: $32.44
  • 50 Day Moving Average: $29.39
  • 200 Day Moving Average: $28.22
  • 52-Week Range: $24.11 - $32.95
  • Trailing P/E Ratio: 127.22
  • Foreward P/E Ratio: 19.43
  • P/E Growth: 1.14
  • Market Cap: $4.71B
  • Outstanding Shares: 145,074,000
Additional Links:

Analyst Ratings

Consensus Ratings for Patheon NV (NASDAQ:PTHN) (?)
Ratings Breakdown: 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $31.80 (1.97% downside)

Analysts' Ratings History for Patheon NV (NASDAQ:PTHN)
Show:
DateFirmActionRatingPrice TargetDetails
12/21/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$31.00View Rating Details
8/23/2016William BlairInitiated CoverageOutperform -> OutperformView Rating Details
8/16/2016Credit Suisse GroupInitiated CoverageNeutral$30.00View Rating Details
8/15/2016Raymond James Financial, Inc.Initiated CoverageOutperform$32.50View Rating Details
8/15/2016Evercore ISIInitiated CoverageBuy$33.00View Rating Details
8/15/2016Wells Fargo & CoInitiated CoverageOutperformView Rating Details
8/15/2016Robert W. BairdInitiated CoverageOutperform$32.00View Rating Details
8/15/2016Piper Jaffray CompaniesInitiated CoverageOverweight$32.50View Rating Details
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00View Rating Details
8/15/2016KeyCorpInitiated CoverageOverweight$33.00View Rating Details
8/15/2016J P Morgan Chase & CoInitiated CoverageOverweight$30.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Patheon NV (NASDAQ:PTHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
12/20/2016Q416$0.39$0.30$510.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Patheon NV (NASDAQ:PTHN)
Current Year EPS Consensus Estimate: $1.41 EPS
Next Year EPS Consensus Estimate: $1.67 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20162$0.34$0.36$0.35
Q1 20172$0.19$0.22$0.21
Q2 20172$0.29$0.37$0.33
Q3 20171$0.38$0.38$0.38
Q4 20172$0.42$0.46$0.44
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Patheon NV (NASDAQ:PTHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Patheon NV (NASDAQ:PTHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2016Paul S LevyDirectorBuy10,000$29.55$295,500.00View SEC Filing  
9/28/2016Paul S LevyDirectorBuy15,000$29.64$444,600.00View SEC Filing  
9/12/2016Paul S LevyDirectorBuy37,000$28.01$1,036,370.00View SEC Filing  
7/26/2016Jll Patheon Co-Investment FundMajor ShareholderBuy815,730$19.85$16,192,240.50View SEC Filing  
7/26/2016Pamela DaleyDirectorBuy48,800$19.85$968,680.00View SEC Filing  
7/21/2016Philip EykermanDirectorBuy28,000$25.00$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Patheon NV (NASDAQ:PTHN)
DateHeadline
nasdaq.com logoPatheon Reaches Analyst Target Price (NASDAQ:PTHN)
www.nasdaq.com - February 24 at 8:34 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statemen (NASDAQ:PTHN)
biz.yahoo.com - February 8 at 9:27 PM
finance.yahoo.com logoCORRECTING and REPLACING PHOTO Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site (NASDAQ:PTHN)
finance.yahoo.com - February 1 at 10:08 PM
capitalcube.com logoPatheon NV breached its 50 day moving average in a Bullish Manner : PTHN-US : January 30, 2017 (NASDAQ:PTHN)
www.capitalcube.com - January 30 at 8:10 AM
capitalcube.com logoETFs with exposure to Patheon NV : January 20, 2017 (NASDAQ:PTHN)
www.capitalcube.com - January 20 at 9:06 PM
capitalcube.com logoPatheon NV breached its 50 day moving average in a Bearish Manner : PTHN-US : January 12, 2017 (NASDAQ:PTHN)
www.capitalcube.com - January 12 at 7:59 PM
capitalcube.com logoPatheon NV :PTHN-US: Earnings Analysis: Q4, 2016 By the Numbers : January 12, 2017 (NASDAQ:PTHN)
www.capitalcube.com - January 12 at 7:59 PM
capitalcube.com logoETFs with exposure to Patheon NV : January 9, 2017 (NASDAQ:PTHN)
www.capitalcube.com - January 9 at 8:04 PM
capitalcube.com logoPatheon NV :PTHN-US: Earnings Analysis: 2016 By the Numbers : January 6, 2017 (NASDAQ:PTHN)
www.capitalcube.com - January 6 at 8:05 PM
finance.yahoo.com logoPatheon to Participate in the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:PTHN)
finance.yahoo.com - January 4 at 3:18 PM
thestreet.com logoInsiders Will Likely Move Pharmaceutical Company Patheon's Stock (NASDAQ:PTHN)
www.thestreet.com - December 30 at 7:42 PM
finance.yahoo.com logoPATHEON N.V. Financials (NASDAQ:PTHN)
finance.yahoo.com - December 29 at 7:22 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 10-K, Annual Report (NASDAQ:PTHN)
biz.yahoo.com - December 23 at 7:31 PM
4-traders.com logoPatheon NV : (PTHN) Slips Ahead of Numbers (NASDAQ:PTHN)
www.4-traders.com - December 22 at 1:14 AM
finance.yahoo.com logoEdited Transcript of PTHN earnings conference call or presentation 20-Dec-16 1:00pm GMT (NASDAQ:PTHN)
finance.yahoo.com - December 21 at 12:03 AM
publicnow.com logoPatheon Reports Growth Across All Segments For Fourth Quarter; Provides Outlook for Fiscal Year 2017 (NASDAQ:PTHN)
us.rd.yahoo.com - December 20 at 2:00 PM
biz.yahoo.com logoQ4 2016 Patheon NV Earnings Release - Before Market Open (NASDAQ:PTHN)
us.rd.yahoo.com - December 20 at 2:00 PM
4-traders.com logoPATHEON N.V. : Financial Statements and Exhibits (form 8-K) (NASDAQ:PTHN)
www.4-traders.com - December 15 at 9:18 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:PTHN)
biz.yahoo.com - December 14 at 8:14 PM
insidermonkey.com logoIs Patheon NV (PTHN) Worthy of Your Portfolio? (NASDAQ:PTHN)
www.insidermonkey.com - December 11 at 6:24 PM
finance.yahoo.com logoCORRECTING and REPLACING Patheon to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on December 20, 2016; Company to Provide Fiscal 2017 Outlook (NASDAQ:PTHN)
finance.yahoo.com - December 2 at 12:02 PM
finance.yahoo.com logoADDING MULTIMEDIA Patheon to Acquire State-of-the-Art Manufacturing Site (NASDAQ:PTHN)
finance.yahoo.com - November 29 at 1:59 PM
investopedia.com logoFour Underrated Stocks That Big Investors Bought in Q3 (NASDAQ:PTHN)
www.investopedia.com - November 21 at 7:31 PM
uk.finance.yahoo.com logoPatheon to Participate in Jefferies Global Healthcare Conference (NASDAQ:PTHN)
uk.finance.yahoo.com - November 4 at 6:33 PM
247wallst.com logoJefferies Biotech and Health Care Momentum Stocks to Buy With Big Upside Potential (NASDAQ:PTHN)
247wallst.com - November 3 at 11:11 AM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Other Events (NASDAQ:PTHN)
biz.yahoo.com - October 14 at 6:41 PM
finance.yahoo.com logoPatheon Announces the Retirement of Stuart Grant (NASDAQ:PTHN)
finance.yahoo.com - October 11 at 7:13 PM
finance.yahoo.com logo8:57 am Patheon announces CFO Stuart Grant plans to retire in 2017 (NASDAQ:PTHN)
finance.yahoo.com - October 11 at 7:13 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:PTHN)
biz.yahoo.com - October 11 at 7:13 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 10-Q, Quarterly Report (NASDAQ:PTHN)
biz.yahoo.com - September 14 at 11:17 AM
4-traders.com logoPatheon : to Participate in Morgan Stanley Global Healthcare Conference (NASDAQ:PTHN)
www.4-traders.com - September 9 at 11:40 AM
finance.yahoo.com logoPatheon to Participate in Morgan Stanley Global Healthcare Conference (NASDAQ:PTHN)
finance.yahoo.com - September 9 at 11:40 AM
publicnow.com logoPatheon Reports Strong Third Quarter 2016 Topline Growth and Margin Expansion (NASDAQ:PTHN)
www.publicnow.com - September 8 at 10:45 AM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:PTHN)
biz.yahoo.com - September 8 at 10:45 AM
benzinga.com logoLake Street Capital Likes Felxion's Lead Drug Candidate, Prescribes A Buy Rating (NASDAQ:PTHN)
www.benzinga.com - September 6 at 11:40 AM
publicnow.com logoPatheon to Announce Third Quarter Fiscal 2016 Financial Results on September 8, 2016 (NASDAQ:PTHN)
www.publicnow.com - August 31 at 12:06 PM
reuters.com logoCinven nears deal to acquire Bioclinica for more than $1.3 billion: sources (NASDAQ:PTHN)
in.reuters.com - August 24 at 6:42 PM
reuters.com logoCinven to acquires pharmaceutical research firm Bioclinica (NASDAQ:PTHN)
www.reuters.com - August 22 at 6:52 PM
bizjournals.com logoActavis recalls diabetes drugs made by Durham-based Patheon (NASDAQ:PTHN)
www.bizjournals.com - August 19 at 6:53 PM
247wallst.com logoWhy Every Analyst in the World Loves Patheon Even After a Strong IPO (NASDAQ:PTHN)
247wallst.com - August 16 at 10:15 AM
finance.yahoo.com logoCoverage initiated on Patheon N.V. by Piper Jaffray, JP Morgan, KeyBanc Capital Mkts, Wells Fargo, Robert W. Baird, Morgan Stanley and UBS (NASDAQ:PTHN)
finance.yahoo.com - August 15 at 7:22 PM
finance.yahoo.com logoMorgan Stanley Expects 'Above-Market Organic Growth' For Patheon, Initiates At Overweight (NASDAQ:PTHN)
finance.yahoo.com - August 15 at 7:22 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:PTHN)
biz.yahoo.com - August 8 at 7:12 PM
moodys.com logoPatheon N.V. -- Moody's affirms DPx Holdings' CFR at B3, downgrades credit facilities and notes. Outlook stable. (NASDAQ:PTHN)
www.moodys.com - August 4 at 7:28 PM
finance.yahoo.com logoPatheon Announces Full Redemption of 8.75%/9.50% Senior PIK Toggle Notes Due May 1, 2020 (NASDAQ:PTHN)
finance.yahoo.com - August 4 at 10:07 AM
tmcnet.com logoPatheon N.V. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (NASDAQ:PTHN)
www.tmcnet.com - July 26 at 10:12 PM
biz.yahoo.com logoPATHEON N.V. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer (NASDAQ:PTHN)
biz.yahoo.com - July 26 at 4:10 PM
4-traders.com logoPatheon : N.V. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (NASDAQ:PTHN)
www.4-traders.com - July 26 at 4:04 PM
finance.yahoo.com logoPatheon N.V. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (NASDAQ:PTHN)
finance.yahoo.com - July 26 at 11:37 AM

Social

What is Patheon NV's stock symbol?

Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."

Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?

12 equities research analysts have issued 1-year price objectives for Patheon NV's shares. Their forecasts range from $30.00 to $33.00. On average, they anticipate Patheon NV's stock price to reach $31.80 in the next twelve months.

When will Patheon NV announce their earnings?

Patheon NV is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Patheon NV stock?

Here are some recent quotes from research analysts about Patheon NV stock:

  • According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (12/22/2016)

  • Jefferies Group LLC analysts commented, "New top-line data suggests GLPG’s potentiator ‘1837 is likely active; still, comparisons to Kalydeco are difficult, and multiple GLPG correctors/ potentiators would still need to work both individually and in concert for their portfolio to represent a meaningful threat to VRTX." (12/21/2016)

  • Morgan Stanley analysts commented, "High operating leverage can drive ~330 bps in EBITDA margin expansion by FY18; we see EPS growth of 58 percent/20 percent in FY17/FY18," analyst Ricky Goldwasser wrote in a note.Goldwasser said the company is poised to expand its CMO share due to its open platform, end-to-end service, quality and global footprint.Related Link: Wells Fargo Initiates Coverage On Patheon At OutperformForward ViewAs such, the analyst believes Patheon can grow its top line at an 11 percent/8 percent CAGR in FY17/FY18, above market growth rates of 5–6 percent, with 209 bps and 121 bps in EBITDA margin expansion in FY17/FY18. The analyst estimates Patheon can grow EBITDA margins from 21.6 percent in FY16 to 24.8 percent in FY18."Patheon is poised to thrive on biologics, the fastest growing area in drug development, given capabilities that span formulation / development as well as API," (8/15/2016)

Who owns Patheon NV stock?

Patheon NV's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.40%), Alyeska Investment Group L.P. (0.63%), Franklin Resources Inc. (0.52%), Janus Capital Management LLC (0.33%), Meru Capital Group LP (0.32%) and State Street Corp (0.27%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman.

Who sold Patheon NV stock? Who is selling Patheon NV stock?

Patheon NV's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Highland Capital Management LP, Fred Alger Management Inc., BlueMar Capital Management LLC, TCW Group Inc. and Alyeska Investment Group L.P..

Who bought Patheon NV stock? Who is buying Patheon NV stock?

Patheon NV's stock was acquired by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Meru Capital Group LP, State Street Corp, Franklin Resources Inc., Friess Associates LLC, GSA Capital Partners LLP, Guggenheim Capital LLC and State Board of Administration of Florida Retirement System. Company insiders that have bought Patheon NV stock in the last two years include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman.

How do I buy Patheon NV stock?

Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Patheon NV stock cost?

One share of Patheon NV stock can currently be purchased for approximately $32.44.

Patheon NV (NASDAQ:PTHN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)

Earnings History Chart

Earnings by Quarter for Patheon NV (NASDAQ:PTHN)

Dividend History Chart

Dividend Payments by Quarter for Patheon NV (NASDAQ:PTHN)

Last Updated on 2/25/2017 by MarketBeat.com Staff